/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

ABVC Biopharma Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.61 0.0078(0.78%) ABVC at 04 Dec 2025 04:24 PM Biotechnology
Lowest Today 2.5
Highest Today 2.5865
Today’s Open 2.55
Prev. Close 2.55
52 Week High 5.48
52 Week Low 0.40
Day’s Range: Low 2.5 High 2.5865
52-Week Range: Low 0.40 High 5.48
1 day return -
1 Week return -4.08
1 month return -9.79
3 month return -
6 month return +63.8
1 year return +416.0
3 year return -62.05
5 year return -
10 year return -

Institutional Holdings

Vanguard Institutional Extnd Mkt Idx Tr 0.63

Vanguard Group Inc 0.47

Geode Capital Management, LLC 0.47

Fidelity Extended Market Index 0.31

XTX Topco Ltd 0.22

Renaissance Technologies Corp 0.18

Northern Trust Corp 0.16

Fidelity Total Market Index 0.11

Fidelity Series Total Market Index 0.10

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

NT Ext Equity Mkt Idx Fd - NL 0.08

Spartan Extended Market Index Pool F 0.08

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.06

State Street Corp 0.05

Spartan Total Market Index Pool G 0.04

Fidelity Nasdaq Composite Index 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

NT Ext Eq Mkt Indx Fd DC Lend T3 0.02

SBI Securities Co Ltd 0.00

Tower Research Capital LLC 0.00

Bank of America Corp 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

Citadel Advisors Llc 0.00

Honkamp Krueger Financial Services Inc 0.00

TWO SIGMA SECURITIES, LLC 0.00

UBS Group AG 0.00

Virtu Financial LLC 0.00

Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 61.97 M

PB Ratio 5.4618

PE Ratio 0.0

Enterprise Value 66.99 M

Total Assets 7.54 M

Volume 41183

Company Financials

Annual Revenue FY23:739259 0.7M, FY22:969783 1.0M, FY21:355797 0.4M, FY20:483045 0.5M, FY19:701719 0.7M

Annual Profit FY23:311017 0.3M, FY22:683368 0.7M, FY21:350711 0.4M, FY20:464329 0.5M, FY19:681582 0.7M

Annual Net worth FY23:-12268660 -12.3M, FY22:-16312374 -16.3M, FY21:-12035851 -12.0M, FY20:-10593584 -10.6M, FY19:-3933240 -3.9M

Quarterly Revenue Q3/2025:795950 0.8M, Q2/2025:0 0.0M, Q1/2025:1966 0.0M, Q3/2024:389276 0.4M, Q2/2024:117142 0.1M

Quarterly Profit Q3/2025:795950 0.8M, Q2/2025:-80832 -0.1M, Q1/2025:1966 0.0M, Q3/2024:388980 0.4M, Q2/2024:116952 0.1M

Quarterly Net worth Q3/2025:-1246513 -1.2M, Q2/2025:-2257022 -2.3M, Q1/2025:-842075 -0.8M, Q3/2024:-186561 -0.2M, Q2/2024:-1012645 -1.0M

Fund house & investment objective

Company Information ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Organisation Biotechnology

Employees 16

Industry Biotechnology

CEO Dr. Uttam Yashwant Patil Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow